Tech Company Financing Transactions
Renalys Pharma Funding Round
Renalys Pharma secured a $38 million Series A funding round on 7/18/2024. Backers included Catalys Pacific, SR One Capital Management and Japan Co-Invest Limited Partnership.
Transaction Overview
Company Name
Announced On
7/18/2024
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to complete its Phase III clinical trial for sparsentan, a promising treatment for IgA nephropathy, in Japan.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3-11, Nihonbashi-honcho2-chome Chuo-ku
Tokyo, 103-0023
Japan
Tokyo, 103-0023
Japan
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Renalys Pharma is a private, late-stage clinical biopharmaceutical company in Japan committed to the development of innovative therapeutics that address unmet needs in the management of renal disease for Japanese and Asian patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
BT Slingsby
Chief Financial Officer
Takeshi Takahashi
Chief Operating Officer
Keisuke Kobayashi
VP - Bus. Development
Ryutaro Shimazaki
Browse more venture capital transactions:
Prev: 7/18/2024: EdgeRunner AI venture capital transaction
Next: 7/18/2024: Notable Systems venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs